From Invisible to Integral: Inviting Clinical Supply Expertise to the Planning Table
By Rachel Grabenhofer, Chief Editor, Clinical Supply Leader
If the clinical supply environment forges leaders, as Part 1 of this discussion demonstrated, the next question is: What do those leaders actually look like — and why are they increasingly valuable beyond the function itself?
For Hargraves, defining what makes someone successful in clinical supply isn’t straightforward, especially compared to commercial roles. “It’s a really interesting question — the phenotype of the clinical supply professional.”
In commercial supply, the profile is more clearly defined. “I know who to hire in commercial… they know SAP, SKUs, and how to forecast large amounts.” The systems are standardized, the scale is larger, and the expectations are more predictable.
Clinical supply operates differently — with smaller batch sizes, shifting assumptions, and far less structural consistency. “I think commercial supply people can also thrive [in clinical], because it's smaller — smaller batch sizes. They can make that conversion.”
But that adaptability doesn’t extend everywhere. “I’ve seen people go from clinical operations into supply and fail… because it’s so task-driven and stressful.”
Success in clinical supply depends less on predefined skillsets and more on mindset — the ability to absorb pressure, navigate ambiguity, and still execute with precision. “I’m looking for attention to detail… someone who’s not easily shaken — really stoic,” Hargraves explains. “And who has a global perspective… you’re moving product all around the world.”
That combination of traits and the environment that shapes them is also what can make clinical supply such a powerful career accelerator. For Hargraves, that progression played out in real time.
What began for her as an entry into a niche function evolved into a series of opportunities across organizations and roles — including a pivotal shift into clinical operations. In that case, her clinical supply background wasn’t incidental. It was the reason she was recruited.
“They said, ‘We need somebody for clinical operations, but we really love your clinical supply experience.’” It’s a pattern she’s seen repeatedly: the problem-solving ability developed in clinical supply translates beyond the function itself.
“As a manager, I would take a clinical supplies person… even if they don’t know clinical operations, because they know how to navigate.” And in high-pressure environments, that experience becomes even more visible. “When everyone else comes to the table stressed… I’m not — because I’ve seen it.”
Ultimately, clinical supply doesn’t just require resilience, it builds it. And in doing so, it produces leaders who can operate well beyond the boundaries of the function.
AI, Forecasting, and the Shift from Data to Judgment
Looking ahead, Hargraves sees opportunity in emerging technologies — but not resolution. “We have so much access now to information. AI has democratized it, and as an executive, I would have wanted that information yesterday.”
From her perspective, the value isn’t just access to data; it’s timing. The earlier leaders can see supply constraints, timelines, and potential risks, the earlier they can act — before those issues begin to impact trials.
As visibility tools surface risk earlier, they don’t distribute accountability; they concentrate it.
Tools can accelerate planning and provide visibility — particularly in areas that have traditionally required time-intensive coordination. “It can calculate out an expiry date, then map all my manufacturing steps. So that planning step — AI could do it. It may not be exactly right, but AI can tell me what my projected dates are.”
But faster data does not remove uncertainty. It shifts where judgment is required — who must act first when forecasts inevitably fail. Even with more information, leaders remain accountable for interpreting outputs, weighing risk, and making decisions under imperfect conditions.
A Seat at the Table
If there is one change Hargraves would prioritize, it is simple — but fundamental. “Clinical supply should be at the planning conversation, with the person who’s leading the clinical trials.” Because the underlying truth has not changed: “Without supply, there is no site. There is no patient,” she reiterates.
Clinical Supply as a Leadership Proving Ground
For clinical supply professionals, much of Hargraves’ perspective will feel familiar. Persistent forecasting gaps, last-minute pressures, and the expectation to remain invisible (until something goes wrong) are not new challenges. What stands out, however, is her reframing of the function: not simply as operational support, but as a rigorous leadership-building role in drug development.
Her experience underscores a critical disconnect that still exists across the industry. While clinical teams prioritize recruitment, timelines, and cost, supply remains an afterthought that is too often underrepresented in early planning. The result is a system that continues to rely on reactive problem-solving rather than proactive design.
At the same time, this environment — an invisible but critical function with high accountability and inconsistent recognition— is precisely what makes clinical supply such a powerful leadership training ground. The ability to manage uncertainty, navigate global complexity, and make decisions under pressure is not incidental; it is foundational to effective leadership.
For clinical supply professionals, the implication is clear: the role is not just operational — it is inherently strategic. But if the function continues to be underrepresented in early planning, part of the opportunity lies in making that value more visible, earlier, and more deliberately.
As the industry looks to emerging tools like AI to improve forecasting and planning, one message remains clear: technology alone will not solve the core issue. Elevating the strategic role of clinical supply — by bringing it to the table earlier and recognizing its central importance to trial success — will be just as critical.
Or as Hargraves puts it: without supply, there is no site, and there is no patient.
Staci Hargraves is an accomplished executive with experience implementing large and AI-derived transformation, enterprise operations, and patient-focused strategies across the pharmaceutical, biotech, clinical, and health-tech sectors. Most recently, she served as SVP/Head of Transformation, demonstrating expertise in enterprise transformation & modernization (R&D, Commercial, Corporate Affairs, Clinical Ops, G&A); operational leadership with P&L, portfolio, and cross-functional accountability; program office & strategic execution for multi-year initiatives; and patient impact, advocacy & equity strategies.
Additional areas of expertise include: executive communications, culture shaping & change leadership; building high-performing global teams across matrixed environments; and AI-enabled operational redesign and workflow optimization. A purpose-driven leader, Hargraves is known for reshaping global operations, defining strategic vision, and translating it into actionable goals while fostering a more efficient, inclusive environment.